# Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)

> **NCT00016744** · PHASE1,PHASE2 · COMPLETED · sponsor: **Children's Hospital of Philadelphia** · enrollment: 12 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Sodium 4-Phenylbutyrate (4PBA)
- **DRUG:** Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00016744
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2009-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00016744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00016744, "Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00016744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*